B. Lacour, Cancer de l'enfant: particularités épidémiologiques

D. Sommelet, J. Clavel, B. Lacour, D. At, and G. Angio, Epidémiologie des cancers de l'enfant Late effects of cancer treatment: methods and techniques for detection, Semin Oncol, vol.31, issue.1, pp.87-90, 1974.

A. Mosijczuk and F. Ruymann, Second Malignancy in Acute Lymphocytic Leukemia, American Journal of Diseases of Children, vol.135, issue.4, pp.313-319, 1960.
DOI : 10.1001/archpedi.1981.02130280003002

A. Meadows, Second Malignant Neoplasms in Childhood Cancer Survivors, Journal of Pediatric Oncology Nursing, vol.6, issue.1, pp.7-11, 1989.
DOI : 10.1177/104345428900600103

S. Garwicz, H. Anderson, J. Olsen, H. Døllner, H. Hertz et al., Second malignant neoplasms after cancer in childhood and adolescence: a population-based casecontrol study in the 5 Nordic countries. The Nordic Society for Pediatric Hematology and Oncology. The Association of the Nordic Cancer Registries, Int J Cancer. Nov, vol.1588, issue.4, pp.672-680, 2000.

K. Koh, K. Yoo, H. Im, K. Sung, H. Koo et al., Characteristics and Outcomes of Second Malignant Neoplasms after Childhood Cancer Treatment: Multi-Center Retrospective Survey, Journal of Korean Medical Science, vol.31, issue.8, pp.1254-61, 2016.
DOI : 10.3346/jkms.2016.31.8.1254

N. Hijiya, K. Ness, R. Ribeiro, and M. Hudson, Acute leukemia as a secondary malignancy in children and adolescents: Current findings and issues, Cancer, vol.1400, issue.1, pp.23-35, 2009.
DOI : 10.1002/cncr.23988

G. Sebahoun, Hématologie clinique et biologique

J. Malfuson, Rôle de la niche mésenchymateuse dans la régulation du phénotype SP des progéniteurs hématopoïétiques humains, Bull Cancer, 2010.

D. Gilliland, C. Jordan, and C. Felix, The molecular basis of leukemia. Hematol Educ Program Am Soc Hematol Am Soc Hematol Educ Program, pp.80-97, 2004.

D. Gilliland, Molecular genetics of human leukemias: New insights into therapy, Seminars in Hematology, vol.39, issue.4
DOI : 10.1053/shem.2002.36921

T. Lapidot, C. Sirard, J. Vormoor, B. Murdoch, T. Hoang et al., A cell initiating human acute myeloid leukaemia after transplantation into SCID mice, Nature, vol.367, issue.6464, 1994.
DOI : 10.1038/367645a0

D. Dick and J. , Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell, Feb Nat Med, vol.173673, issue.64647, pp.645-653, 1997.

C. Scholl, D. Gilliland, and S. Fröhling, Deregulation of Signaling Pathways in Acute 65

C. Pui, W. Carroll, S. Meshinchi, and R. Arceci, Biology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An Update, Journal of Clinical Oncology, vol.29, issue.5, pp.551-65, 2011.
DOI : 10.1200/JCO.2010.30.7405

C. Pui, W. Carroll, S. Meshinchi, and R. Arceci, Biology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An Update, Journal of Clinical Oncology, vol.29, issue.5, pp.551-65, 2011.
DOI : 10.1200/JCO.2010.30.7405

H. Poirel and O. Bernard, Implication des gènes du CBF dans la leucémogénèse, pp.30-36, 2000.

R. Wright and A. Vaughan, A systematic description of MLL fusion gene formation, Critical Reviews in Oncology/Hematology, vol.91, issue.3
DOI : 10.1016/j.critrevonc.2014.03.004

U. Creutzig, M. Van-den-heuvel-eibrink, B. Gibson, M. Dworzak, S. Adachi et al., Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood Vardiman JW. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms, Chem Biol Interact, vol.120184, issue.1612, pp.3187-205, 2010.

J. Bennett, D. Catovsky, M. Daniel, G. Flandrin, D. Galton et al., Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group, British Journal of Haematology, vol.1, issue.4, pp.451-459, 1976.
DOI : 10.1111/j.1365-2141.1976.tb03563.x

J. Vardiman, J. Thiele, D. Arber, R. Brunning, M. Borowitz et al., The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes, Blood, vol.114, issue.5, pp.937-51, 2009.
DOI : 10.1182/blood-2009-03-209262

D. Arber, A. Orazi, R. Hasserjian, J. Thiele, M. Borowitz et al., The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood, vol.127, issue.20, pp.2391-405, 2016.
DOI : 10.1182/blood-2016-03-643544

B. Lange, N. Kobrinsky, D. Barnard, D. Arthur, J. Buckley et al., Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891, Blood, vol.91, issue.2, pp.608-623, 1998.

M. Adams, M. Jenney, L. Lazarou, R. White, S. Birdsall et al., Acute Myeloid Leukaemia after Treatment for Acute Lymphoblastic Leukaemia in Girl with Bloom Syndrome, Journal of Genetic Syndromes & Gene Therapy, vol.04, issue.08, 2013.
DOI : 10.4172/2157-7412.1000177

F. Miélot and O. Fenneteau, Syndromes myélodysplasiques de l'enfant. Rev Fr Lab, 1996.

V. Mialou, T. Leblanc, P. De-latour, R. Dalles, J. Socié et al., Aplasies médullaires constitutionnelles. EMC -Hématologie, pp.1-12, 2011.

T. Leblanc and L. Da-costa, Anémie de Blackfan-Diamond : actualités. Rev Oncol Hématologie Pédiatrique, pp.195-204, 2014.

V. Mialou, T. Leblanc, R. Latour, . De, J. Dalle et al., La dyskératose congénitale : mise au point. Arch Pédiatrie, pp.299-306, 2013.

H. Grünwald and F. Rosner, Acute myeloid leukemia following treatment of hodgkin's disease. A review, Cancer, vol.20, issue.4, pp.676-83, 1982.
DOI : 10.1002/1097-0142(19820815)50:4<676::AID-CNCR2820500410>3.0.CO;2-B

C. Pui, F. Behm, S. Raimondi, R. Dodge, S. George et al., Secondary Acute Myeloid Leukemia in Children Treated for Acute Lymphoid Leukemia, New England Journal of Medicine, vol.321, issue.3, 1989.
DOI : 10.1056/NEJM198907203210302

C. Felix, C. Kolaris, and N. Osheroff, Topoisomerase II and the etiology of chromosomal translocations. DNA Repair, pp.9-101093, 2006.

C. Felix, M. Smith, L. Rubinstein, R. Ungerleider, and P. Pourquier, Secondary leukemias induced by topoisomerase-targeted drugs Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks Molecular determinants of response to topoisomerase II inhibitors, Biochim Biophys Acta. Med Pediatr Oncol. Bull Cancer, vol.140023, issue.211, pp.1-3233, 1994.

P. Pourquier, A. Meadows, E. Baum, F. Fossati-bellani, D. Green et al., Alkylating agents Bull Cancer (Paris), pp.1237-1251, 2011.

G. Schellong, M. Riepenhausen, U. Creutzig, J. Ritter, J. Harbott et al., Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group., Journal of Clinical Oncology, vol.15, issue.6, pp.2247-53, 1997.
DOI : 10.1200/JCO.1997.15.6.2247

L. Deley, M. Leblanc, T. Shamsaldin, A. Raquin, M. Lacour et al., Risk of Secondary Leukemia After a Solid Tumor in Childhood According to the Dose of Epipodophyllotoxins and Anthracyclines: A Case-Control Study by the Soci??t?? Fran??aise d???Oncologie P??diatrique, Journal of Clinical Oncology, vol.21, issue.6, pp.1074-81, 2003.
DOI : 10.1200/JCO.2003.04.100

K. Schmiegelow, M. Levinsen, A. Attarbaschi, A. Baruchel, M. Devidas et al., Second Malignant Neoplasms After Treatment of Childhood Acute Lymphoblastic Leukemia, Journal of Clinical Oncology, vol.31, issue.19, pp.312469-76, 2013.
DOI : 10.1200/JCO.2012.47.0500

M. Gauthier-villars and D. Stoppa-lyonnet, Genetic predisposition in children cancers in 2011, Bull Cancer, issue.5, pp.459-475, 2011.

T. Leblanc and R. Berger, Molecular cytogenetics of childhood acute myelogenous leukaemias, European Journal of Haematology, vol.85, issue.Suppl 1, pp.1-13, 1997.
DOI : 10.1111/j.1600-0609.1997.tb00953.x

F. Mugneret, P. Callier, and B. Favre-audry, Anomalies chromosomiques dans les leuc??mies aigu??s my??lo??des, Pathologie Biologie, vol.51, issue.6, pp.314-342, 2003.
DOI : 10.1016/S0369-8114(03)00114-7

S. Zeichner and M. Arellano, Secondary Adult Acute Myeloid Leukemia: a Review of Our Evolving Understanding of a Complex Disease Process, Current Treatment Options in Oncology, vol.117, issue.4, pp.11864-11879, 2015.
DOI : 10.1007/s11864-015-0355-3

T. Butel, P. Ou, C. Fayech, N. Haddy, D. Valteau-couanet et al., Toxicités cardiaques des anthracyclines en oncologie pédiatrique : de la clinique à la pharmacogénétique. Rev Oncol Hématologie Pédiatrique, pp.70-77, 2015.

Z. Huma, F. Boulad, P. Black, G. Heller, and C. Sklar, Growth in children after bone marrow transplantation for acute leukemia, Blood. Jul, vol.1586, issue.2, pp.819-843, 1995.

C. Oudin, P. Auquier, Y. Bertrand, P. Chastagner, J. Kanold et al., Late thyroid complications in survivors of childhood acute leukemia. An L.E.A. study. Haematologica, pp.747-56, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01358588

H. Sudour-bonnange, A. Vanrenterghem, F. Nobili, V. Guigonis, B. Boudailliez et al., Renal late effects in patients treated for cancer in childhood] Bull Cancer (Paris) FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies, Leuk Res, vol.10226, issue.7 88, pp.627-662, 2002.

D. Pastore, G. Specchia, P. Carluccio, A. Liso, A. Mestice et al., FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience, Ann Hematol, vol.82, issue.4, pp.231-236, 2003.

P. Chevallier, J. Delaunay, P. Turlure, A. Pigneux, M. Hunault et al., Primary Resistant or Relapsed Acute Myeloid Leukemia, Journal of Clinical Oncology, vol.26, issue.32, pp.5192-5199, 2008.
DOI : 10.1200/JCO.2007.15.9764

D. Aguilera, C. Vaklavas, A. Tsimberidou, S. Wen, L. Medeiros et al., Pediatric Therapy-related Myelodysplastic Syndrome/Acute Myeloid Leukemia, Journal of Pediatric Hematology/Oncology, vol.31, issue.11, pp.803-814, 2009.
DOI : 10.1097/MPH.0b013e3181ba43dc

D. Barnard, Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation. Blood Treatment-related myelodysplastic syndrome/acute myeloid leukemia in survivors of childhood cancer ? An update, Leuk Lymphoma, vol.100, issue.2, pp.427-461, 2002.

R. Allodji, B. Schwartz, C. Veres, N. Haddy, C. Rubino et al., Risk of Subsequent Leukemia After a Solid Tumor in Childhood: Impact of Bone Marrow Radiation Therapy and Chemotherapy, International Journal of Radiation Oncology*Biology*Physics, vol.93, issue.3, pp.658-67, 2015.
DOI : 10.1016/j.ijrobp.2015.07.2270

E. Hulegårdh, C. Nilsson, V. Lazarevic, H. Garelius, P. Antunovic et al., Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: A report from the Swedish Acute Leukemia Registry, American Journal of Hematology, vol.102, issue.3, pp.208-222, 2015.
DOI : 10.1002/ajh.23908

E. Santo, A. Chacim, S. Ferreira, I. Leite, L. Moreira et al., Effect of therapy-related acute myeloid leukemia on the outcome of patients with acute myeloid leukemia, Oncol Lett. 2016, vol.12, issue.1, pp.262-270

H. Kantarjian, E. Estey, and M. Keating, Treatment of therapy-related leukemia and myelodysplastic syndrome, Hematol Oncol Clin North Am. Feb, vol.7, issue.1, pp.81-107, 1993.

N. Kröger, R. Brand, A. Van-biezen, A. Zander, J. Dierlamm et al., Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation, Haematologica, vol.94, issue.4, pp.542-551, 2009.
DOI : 10.3324/haematol.2008.000927

M. Elliott, L. Letendre, A. Tefferi, W. Hogan, C. Hook et al., Therapyrelated acute promyelocytic leukemia: observations relating to APL pathogenesis and therapy*: Therapy-related acute promyelocytic leukemia, Eur J Haematol, 2012.

C. Schoch, W. Kern, S. Schnittger, W. Hiddemann, and T. Haferlach, Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML, Leukemia, vol.18, issue.1, pp.120-125, 2004.
DOI : 10.1038/sj.leu.2403187

S. Davies, Therapy-related leukemia associated with alkylating agents, Medical and Pediatric Oncology, vol.18, issue.5, pp.536-576, 2001.
DOI : 10.1002/mpo.1126

A. Allard, N. Haddy, L. Deley, M. Rubino, C. Lassalle et al., Role of Radiation Dose in the Risk of Secondary Leukemia After a Solid Tumor in Childhood Treated Between 1980 and 1999, International Journal of Radiation Oncology*Biology*Physics, vol.78, issue.5, pp.1474-82, 1980.
DOI : 10.1016/j.ijrobp.2009.09.032

J. Dunst, S. Ahrens, M. Paulussen, C. Rübe, W. Winkelmann et al., Second malignancies after treatment for Ewing???s sarcoma: a report of the CESS-studies, International Journal of Radiation Oncology*Biology*Physics, vol.42, issue.2, pp.379-84, 1998.
DOI : 10.1016/S0360-3016(98)00228-4

S. Bhatia, M. Krailo, Z. Chen, L. Burden, F. Askin et al., Therapyrelated myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group, Blood, 2007.

M. Link, S. Donaldson, R. Kempson, J. Wilbur, and B. Glader, Acute nonlymphocytic leukemia developing during the course of Ewing's sarcoma, Medical and Pediatric Oncology, vol.221, issue.3, pp.46-51, 1984.
DOI : 10.1002/mpo.2950120310

F. Navid, C. Billups, T. Liu, M. Krasin, and C. Rodriguez-galindo, Second cancers in patients with the Ewing sarcoma family of tumours, European Journal of Cancer, vol.44, issue.7, 1990.
DOI : 10.1016/j.ejca.2008.02.027

M. Paulussen, S. Ahrens, M. Lehnert, D. Taeger, H. Hense et al., Second malignancies after ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study, Ann Oncol Off J Eur Soc Med Oncol ESMO, 2001.

D. Green, C. Sklar, J. Boice, J. Mulvihill, J. Whitton et al., Ovarian Failure and Reproductive Outcomes After Childhood Cancer Treatment: Results From the Childhood Cancer Survivor Study, Journal of Clinical Oncology, vol.27, issue.14, pp.2374-81, 2009.
DOI : 10.1200/JCO.2008.21.1839

G. Michel, Y. Bertrand, A. Contet, M. Poiree, N. Sirvent et al., suivi prolongé après traitement d'une leucémie aiguë de l'enfance : structuration, résultats et perspectives. Rev Oncol Hématologie Pédiatrique, pp.90-98, 2014.

T. Adam-de-beaumais, A. Baruchel, and E. Jacqz-aigrain, Approches méthodologiques en pharmacogénétique : le modèle des leucémies aiguës lymphoblastiques de l'enfant. Rev Oncol Hématologie Pédiatrique, pp.215-235, 2015.

J. Perentesis, Genetic predisposition and treatment-related leukemia, Medical and Pediatric Oncology, vol.28, issue.5, pp.541-549, 2001.
DOI : 10.1002/mpo.1127

S. Bhatia, Therapy-Related Myelodysplasia and Acute Myeloid Leukemia, Seminars in Oncology, vol.40, issue.6, pp.666-75, 2013.
DOI : 10.1053/j.seminoncol.2013.09.013

N. Winick, R. Mckenna, J. Shuster, N. Schneider, M. Borowitz et al., Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide., Journal of Clinical Oncology, vol.11, issue.2, pp.209-226, 1993.
DOI : 10.1200/JCO.1993.11.2.209

B. Kushner, A. Zauber, and C. Tan, Second malignancies after childhood Hodgkin's disease: The memorial sloan-kettering cancer center experience, Cancer, vol.310, issue.7, pp.1364-70, 1988.
DOI : 10.1002/1097-0142(19881001)62:7<1364::AID-CNCR2820620721>3.0.CO;2-T

C. Panizo, A. Patiño, M. Calasanz, J. Rifón, L. Sierrasesumaga et al., Emergence of secondary acute leukemia in a patient treated for osteosarcoma: implications of germline TP53 mutations, Medical and Pediatric Oncology, vol.84, issue.3, pp.165-174, 1998.
DOI : 10.1002/(SICI)1096-911X(199803)30:3<165::AID-MPO7>3.0.CO;2-F

$. Leucémie, $. , and L. , 21)(q22;q22), *PML/RARA inv(16)(p13.1q22)p22;q23),*MLLT3/KMT2A t(6;9)(p23;q34),*DEK/NUP214 inv(3)(q21q26,2),*GATA2,MECOM t